How HIV becomes resistant to today's HIV medicines in Kenya
Official title: HIV Drug Resistance in the New Antiretroviral Therapy Era in Kenya
Funded at Miriam Hospital · NIH-11192370 · Data updated 2026-11-12
Learning how HIV develops resistance to newer HIV treatments in Kenya so people can keep getting medicines that work.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Miriam Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | September 12, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $502,412 |
| NIH project number | 5R01AI186632-02 |
| Project ID | NIH-11192370 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV in Kenya, including those currently on antiretroviral therapy or experiencing treatment failure, would be the primary candidates for participation.
✕Less likely to help
People without HIV or those receiving care outside the Kenyan clinics included in this work are unlikely to directly benefit from participation.
What this research studies
This project follows people and virus samples in Kenya to see which HIV strains develop resistance now that newer drugs like dolutegravir are widely used. Researchers will collect blood samples, measure viral load and resistance mutations, and link results to treatment history and care settings. The team will compare resistance across regions, drug regimens, and special situations such as HIV-TB coinfection to understand where problems arise. The goal is to inform better treatment choices and monitoring for people living with HIV in Kenya.
Why it matters
Potential benefit: Could help clinicians choose and preserve effective HIV treatments and guide policies to limit the spread of resistant virus in Kenya.
How similar studies have gone: Previous research documented drug resistance to older HIV drugs, but tracking resistance now that dolutegravir is widely used is more recent and less well characterized.
Where this research is happening
-
Miriam Hospital
Providence, United States Active
Researchers
- Principal investigator: Kantor, Rami — Miriam Hospital
- Study coordinator: Kantor, Rami
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.